AI-driven protein discovery platform Cradle raises $73M https://t.co/dkUMcQ7hT8
AI is reshaping biology in ways we never thought possible. That’s why we’re partnering with @stefvangrieken and the @cradlebio team on their $73M Series B. 🧬 Cradle’s AI platform helps scientists design new therapies and sustainable materials at 12x the speed they could before.… https://t.co/vxoXywVEmN
Major biopharma companies, including Genentech and Gilead, are using AI models to find new medicines, optimize trial designs, and boost manufacturing efficiency. We're featured alongside them in this ITIF report, which touches on some AI tools we're building for gene therapies. https://t.co/h0OG4qlpmO


Cradle, a European startup specializing in AI-driven protein discovery, has successfully raised $73 million in a Series B funding round led by IVP. The company, which employs 43 people, currently collaborates with 21 customers on 31 protein projects. This funding aims to accelerate the development of new therapies and sustainable materials through advanced AI technologies, allowing scientists to work at a speed 12 times faster than traditional methods. Major biopharma companies, including Genentech and Gilead, are also utilizing AI models to enhance drug discovery and manufacturing processes.